Atherogenic profile in preeclampsia
| dc.contributor.author | Var A. | |
| dc.contributor.author | Kuşcu N.K. | |
| dc.contributor.author | Koyuncu F. | |
| dc.contributor.author | Uyanik B.S. | |
| dc.contributor.author | Onur E. | |
| dc.contributor.author | Yildirim Y. | |
| dc.contributor.author | Oruç S. | |
| dc.date.accessioned | 2025-04-10T11:18:03Z | |
| dc.date.available | 2025-04-10T11:18:03Z | |
| dc.date.issued | 2003 | |
| dc.description.abstract | Atherosis is accepted to underlie the pathogenesis of preeclampsia, therefore we aimed to determine malonyldialdehyde (MDA) levels as a marker of lipid peroxidation, and lipoprotein(a) (Lp(a)), apolipoprotein A-1 (Apo A-1) and apolipoprotein B (Apo B) levels as a marker of atherogenic profile in preeclamptic and normal pregnant women. Twenty preeclamptic and 20 gestational-age matched normal pregnant patients were enrolled in the study, mean gestational ages for the preeclamptic and the control group were 33.9±1.4 and 35.5±0.7 weeks, respectively. Blood was withdrawn from the patients soon after diagnosis, and from the controls at their routine prenatal visits. MDA levels was significantly higher in preeclamptic patients (P=0.0003), but no difference was observed in Apo A-1 and Apo B and Lp(a) levels between the 2 groups. We consider that higher MDA was due to oxidative stress seen in preeclampsia, and similar Apo A-1 and Apo B and Lp(a) levels were due to lack of systemic atherosis. | |
| dc.identifier.DOI-ID | 10.1007/s00404-002-0317-4 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/53161 | |
| dc.publisher | Springer Verlag | |
| dc.title | Atherogenic profile in preeclampsia | |
| dc.type | Article |